Targets › CYP11A1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and…. (UniProt, P05108)
Open in Phaseline: the race on CYP11A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | Mitotane Cytochrome P450 11A1 inhibitor; Cytochrome P450 11B1 inhibitor | CYP11A1, CYP11B1 | Phase 2 | Adrenal Cortical Carcinoma | Dec 2026 |
Adrenal Cortical Carcinoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.